Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Somatrogon - OPKO Health

Drug Profile

Somatrogon - OPKO Health

Alternative Names: hGH-CTP; Human growth hormone-CTP; Lagova; MOD-4023; PF-06836922; Somatropin long-acting - OPKO Health

Latest Information Update: 03 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Modigene
  • Developer OPKO Health
  • Class Biological proteins; Growth hormones; Hormonal replacements; Obesity therapies
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity No

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 21 Jan 2019 Opko Biologics plans a phase I trial in healthy volunteers in February 2019 (NCT03810664)
  • 21 Aug 2018 Opko Biologics terminates a phase III trial as the main study was completed and sufficient safety data had been generated in Somatotropin deficiency (in adults) in USA, United Kingdom, Austria, Greece, Hungary, Netherlands, Poland, Slovakia, Israel and Spain (SC) (NCT01909479)
  • 03 Aug 2018 OPKO Health completes enrolment in its global phase III trial for somatotrophin deficiency
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top